Why in news?
A team of international researchers recently reported that a self‑reinforcing loop between certain immune cells lies at the heart of Sjögren’s disease. In people with this autoimmune disorder the immune system mistakenly produces antibodies against a protein called Ro60. The study found that Ro60‑reactive CD4+ T cells drive B cells to produce anti‑Ro60 antibodies, and the resulting immune complexes stimulate more T cells. Breaking this vicious cycle could allow targeted therapies that avoid the broad immunosuppression used today.
Background
Sjögren’s disease, also called Sjögren’s syndrome, is a chronic autoimmune disorder in which the immune system attacks exocrine glands that produce saliva and tears. The condition most often affects women between 45 and 55 years of age and is frequently associated with other autoimmune diseases. Common symptoms include dry eyes, dry mouth, fatigue, joint pain and swelling. Over time patients can develop dental cavities, fungal infections, liver or kidney problems and in rare cases lymphoma.
The disease is named after the Swedish ophthalmologist Henrik Sjögren, who in 1933 described 19 patients with keratoconjunctivitis sicca – a combination of dry eyes and dry mouth. His doctoral thesis initially received little attention but a translation published a decade later brought wider recognition. Today Sjögren’s is understood as a systemic disorder involving immune‑mediated damage to moisture‑producing glands and other tissues.
Key points of the new study
- Self‑reinforcing loop: Researchers observed that CD4+ T cells specific to the Ro60 protein activate B cells to produce anti‑Ro60 antibodies. When these antibodies bind the Ro60 antigen they form immune complexes that are taken up by antigen‑ presenting cells, stimulating more T cells. This loop keeps the disease active.
- Cross‑ethnic consistency: The mechanism was seen in both Japanese and Caucasian patients, suggesting a common disease pathway across different populations.
- Therapeutic implications: By targeting either the Ro60‑specific T cells or the B cells that produce the antibodies, future therapies might stop the cycle and reduce the need for broad immunosuppressive drugs.
Management of Sjögren’s disease
Current treatment focuses on relieving dryness and controlling systemic features. Artificial tears and saliva substitutes help ease discomfort, while punctal plugs can slow tear drainage. In more severe cases doctors prescribe medications that stimulate saliva (pilocarpine) or suppress the immune response, such as corticosteroids and immunosuppressants. Maintaining good oral hygiene, staying hydrated and regular medical follow‑up are crucial.
Conclusion
The discovery of a self‑sustaining immune loop provides fresh insight into why Sjögren’s disease becomes chronic. It also offers hope that future treatments can be more precise, targeting the cells responsible for sustaining the disease instead of suppressing the entire immune system.